Roswell Park is one of only 4% of cancer centers designated as a Comprehensive Cancer Center by the National Cancer Institute and was recently awarded the highest possible rating — “Exceptional” — during its five-year Cancer Center Support Grant renewal. This recognition underscores the center’s commitment to providing incredible patient care and working toward the end of cancer as we know it.
When you fundraise for or donate to Roswell Park through Empire State Ride, you’re ultimately making a worldwide impact. Innovative research projects and groundbreaking clinical trials are expensive and dollars raised through fundraisers like Empire State Ride transform ideas and hypotheses into new treatments and exceptional care.
Through regional, national and global collaboration, the funds that come to Roswell Park spearhead efforts that will change the way we prevent, diagnose and treat cancers of all kinds everywhere. After all, we’re all on the same side in the fight against cancer.
Roswell Park is on the cutting edge of cancer treatment and positioned to become a global destination for innovative cancer care like cellular therapy, an emerging and rapidly expanding form of immunotherapy. The pioneering minds at Roswell Park are leading breakthrough studies examining promising new cellular therapy techniques and applications that have potential to bring more effective, less invasive treatment options to patients.
As part of Roswell Park’s commitment to advancing cell therapy, the GMP Engineering & Cell Manufacturing (GEM) Facility opened in January 2025, bringing 14 new cell manufacturing spaces — also called clean rooms — to expand the six already on campus. This robust new space allows for the in-house production of cells to drive innovation in cell therapy. The GEM Facility is the first of its kind in New York State and will bring treatments and innovations to more patients in New York and across the country faster than ever.
Support from ESR brings these brilliant contributions to cancer patients and empowers researchers to imagine new ways to treat and cure cancers.
Research for the innovative brain cancer vaccine, SurVaxM, began more than a decade ago in the labs of Roswell Park, with clinical trials starting in 2012. The vaccine uses the innate genius of a patient’s immune system to target a protein called survivin, which helps cancer cells survive. Findings from a single-arm phase 2A study showed that the vaccine, when combined with standard therapy, resulted in significantly longer survival compared to standard therapy alone. In 2024, SurVaxM received Fast-Track status from FDA.
Today, the phase 2B randomized SURVIVE trial is currently underway at Roswell Park and other centers. (not accepting new patients). SurVaxM is also being evaluated in early-phase studies of adult patients with multiple myeloma (not accepting new patients), some neuroendocrine tumors and in pediatric patients with certain types of brain tumors.
Funds raised through Empire State Ride are managed by the Roswell Park Alliance Foundation, the 501(c)(3) not-for-profit organization which manages all donations made to Roswell Park. The Foundation ensures that every donation is put to the best possible use. It’s earned the highest possible rating on Charity Navigator for nine consecutive years.
When you make the commitment to become an Empire State Ride road warrior, you’re making an impact on the future of cancer research and saving lives. The funds raised by our riders support cutting-edge cancer research at America’s first cancer center dedicated to research, Roswell Park Comprehensive Cancer Center.
When clinical trials identify effective treatments, these treatments will eventually become the new standard of care that will be offered to future patients. One of the latest clinical trials Roswell Park is leading is SurVaxM, an innovative brain cancer vaccine.
This trial is bringing hope to individuals battling some of the most aggressive forms of brain cancer. This unique immunotherapy treatment created at Roswell Park will soon impact cancer patients across the country, using the body’s own immune system to fight the harmful cells.
The adult clinical trial for SurVaxM has advanced into phase 2B for newly diagnosed glioblastoma patients. The randomized, multicenter trial is being offered to over 250 patients in 15 centers in the U.S. and China.
Kids battling brain cancers will also have a chance to see how SurVaxM can help them. Roswell Park is partnering with the Pediatric Brain Tumor Consortium, which will expand the current trial to reach cancer centers across the U.S. and Canada. Through this phase 1 trial, which began in early 2022, pediatric patients will have a chance to take advantage of this vaccine which had previously only been available in Buffalo.